International journal of breast cancer
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region: A Retrospective Study (TREASURE Study)
By Dawoud E, Calaud F, Fadlelseid AA and 9 others.
Abstract
Background
Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has been approved for advanced/metastatic breast cancer (ABC) treatment. However, real-world data on its use in the Arabian Gulf region are limited.
Methods
The TREASURE study, a retrospective, multicenter study, evaluated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) ABC treated with palbociclib + endocrine therapy (ET) in the Arabian Gulf. Data were abstracted from the medical records of eligible patients from 7 selected sites across Arabian Gulf countries. The study evaluated patient demographics, clinical characteristics, treatment patterns, and clinical outcomes in those who initiated palbociclib + ET from April 2015 to September 2019.